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Abstract
Background Esophageal endoscopic submucosal dissec-
tion (ESD) has rarely been reported for the treatment of
cirrhotic patients.
Aim To report the results of ESD treatment of superficial
esophageal neoplasms (SENs) for cirrhotic patients.
Methods Forty patients with 50 consecutive SENs under-
going 46 sessions of ESD were retrospectively reviewed.
The cirrhotic group included eight patients (11 SENs) with
liver cirrhosis consisting of six patients classified as Child-
Pugh class A liver cirrhosis and two patients classified as
class B liver cirrhosis. Four patients (6 SENs) had coex-
isting esophageal varices. Parameters were compared
between the cirrhotic patients and the non-cirrhotic con-
trols (32 patients, 39 SENs).
Results Platelet counts of the cirrhotic group were signif-
icantly lower, while international normalized ratio was
significantly higher. When the cirrhotic group and non-
cirrhotic group were compared, the mean tumor length (4
vs. 3.7 cm, p = 0.56) and median procedure time (15.1 vs.
11.5 min/cm2, p = 0.30) were similar. The en bloc
resection rates were 81.8 and 89.7 % (p = 0.60). Within
the cirrhotic group, both lesions without en bloc resection
were patients with esophageal varices. The rates of sub-
mucosal disease for the cirrhotic group and non-cirrhotic
groups were 54.5 and 25.6 % (p = 0.064), respectively,
while the R0 resection rates were 77.8 and 94.3 %
(p = 0.16), respectively. The two lesions without R0
resection in cirrhotic group had positive vertical but not
horizontal margins due to submucosal invasion. Intrapro-
cedural bleeding occurred more frequently in cirrhotic
patients than non-cirrhotic patients (18.2 vs. 0 %,
p = 0.045). None of the patients suffered from esophageal
perforation, postoperative bleeding, or death that was
related to the ESD.
Conclusion Esophageal ESD seems to be safely and can be
effectively performed on cirrhotic patients, particularly
those without severe liver dysfunction.
Keywords Endoscopic submucosal dissection 
Esophagus  Esophageal varices  Liver cirrhosis 
Superficial esophageal neoplasm
Introduction
Alcohol and smoking are the two main etiological factors
associated with esophageal squamous cell carcinoma
(ESCC). This alcohol-smoking combination also predis-
poses individuals to the occurrence of liver cirrhosis [1].
The rate of liver cirrhosis in patients with esophageal
cancer has been reported to be 7 % in a surgical series and
14.3 % in a laparoscopic staging series [2, 3].
Both T1a and T1b ESCC are designated as superficial
esophageal neoplasms (SENs) regardless of lymph node or
distant organ metastasis [4]. SENs are increasingly
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detected due to advances in diagnostic techniques and the
development of screening programs for high-risk patients
[5, 6]. Endoscopic submucosal dissection (ESD) has
recently been accepted as a treatment for SENs because it
is possible to avoid esophagectomy [7, 8]. However, the
technique used for esophageal ESD is very complicated
and carries a substantial risk of bleeding (2.1 %) and per-
foration (5 %) [9]. Occurrence of severe delayed bleeding
after ESD is also possible [10]. It seems possible that the
use of ESD to treat patients with cirrhosis may carry a
higher risk of these complications due to coagulopathy, a
reduced platelet count, and/or the presence of coexisting
esophageal varices (EVs) [11]. Based on these factors,
cirrhotic patients with SENs may have been excluded from
ESD treatment by some endoscopists. To our knowledge,
the use of esophageal ESD to treat cirrhotic patients has
only been reported in one case series [12]. The feasibility
of esophageal ESD in cirrhotic patients remains unclear,
and how the results obtained treating cirrhotic patients
compare with those for non-cirrhotic patients remains
unknown. The aims of this retrospective study are to report
the efficacy and safety of using ESD to treat SENs present
in cirrhotic patients and to compare the outcome of the
procedure with that of patients without liver cirrhosis.
Materials and Methods
From January 2012 to July 2015, a total of 40 patients with
50 consecutive SENs underwent 46 sessions of ESD; these
were retrospectively identified from a computer database at
the Therapeutic Endoscopic Center of Chang Gung
Memorial Hospital-Linkou Branch. Twenty-seven patients
(67.5 %) had synchronous (n = 21) or metachrnous
(n = 6) head and neck cancers with the SENs being
diagnosed on routine screening endoscopy. All patients
underwent endoscopic ultrasound (EUS) and computed
tomography to allow staging before ESD. The patients with
biopsy results indicating ESCC also underwent positron
emission tomography-computed tomography. The inclu-
sion criteria for ESD were: (1) no lymph node or distant
organ metastasis on the pretreatment image studies and (2)
those patients with mucosal diseases based on EUS, or
those patients with submucosal disease who refused
esophagectomy (n = 4, two had liver cirrhosis). The
exclusion criteria were that the patient refused to provide
inform consent for the ESD.
Among the included patients, eight patients (11 SENs,
10 sessions of ESD) with liver cirrhosis were classified as
the cirrhotic group, which was made up of six patients with
Child-Pugh class A (CP-A) liver cirrhosis and two patients
with Child-Pugh class B (CP-B) liver cirrhosis (Table 1).
Liver cirrhosis was diagnosed for all patients based on
ultrasonographic findings, the presence of EVs in four
patients (6 SENs), and histological proof in three patients
(at a previous resection of their hepatomas, 4 SENs). In
addition to alcohol as the etiological factor of liver cir-
rhosis, three patients with hepatomas also had chronic
hepatitis B infection. The remaining 32 patients (39 SENs,
36 sessions of ESD) without liver cirrhosis were classified
as the non-cirrhotic group. The study was approved by the
Institutional Review Board of Chang Gung Memorial
Hospital (104-0308C).
None of the patients had preoperative ascites or
encephalopathy. The patient characteristics of cirrhotic
group are listed in Table 1. The SENs of the cirrhotic
group were numbered in chronological order according to
the ESD procedures performed. Two patients with three
(SEN 2, 3, and 5) and two (SEN 8 and 9) SENs underwent
three and one endoscopic sessions of ESD, respectively.
Before ESD, a fresh-frozen plasma and platelet transfusion
were given in one CP-B patient (SEN 6). The shape and
size of EVs are presented according to the classification
defined by the Japanese Research Society of Portal
Hypertension [13]; that is, Form-1 (F-1), F-2, or F-3. The
two CP-B patients (SEN 6 and 7) had already received
several sessions of endoscopic variceal ligation (EVL)
before the ESD. Therefore, the shape and size of the EVs at
ESD were F-1 in five procedures (SEN 1, 2, 3, 5, and 7)
and F-2 in one procedure (SEN 6). The relationship
between SENs and varices was illustrated in Fig. 1a–c. For
those patients with coexistent EVs, EVL was performed by
starting the application of the bands at the esophagocardiac
junction (ECJ) and working upwards in a helical fashion
just prior to the ESD in the same endoscopic session using
multiband ligators (Cook Medical or Boston Scientific
Corp.) for all but one patient (SEN 7). EVL was not per-
formed for the patient with SEN 7 because the circumfer-
ential SEN (6 cm in length) involved the ECJ.
All ESD procedures were performed by a single endo-
scopist (Tsou YK), and the study started from his first case
of esophageal ESD. The endoscopist sought advise from
two skilled ESD endoscopists (Ohata K and Fu KI) when
there was difficulty with the ESD procedure. The details of
the ESD procedure are similar to those described in our
previous report [14]. The submucosal injection fluid was a
glycerol solution plus indigo carmine with or without
epinephrine (0.0004 %). ESD was performed mainly using
an insulated tip 2 (IT2) knife (KD-611L, Olympus). En
bloc resection was defined as completed target resection in
one piece. A complete resection was described as R0 when
all the resection margins were free of tumor cells. Proce-
dural complications included major bleeding and perfora-
tion. Major bleeding was defined as the necessity for a
blood transfusion during the procedure or the presence of
post-procedural bleeding requiring endoscopic or surgical
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hemostasis. Perforation was defined as seeing the structures
of the mediastinum endoscopically during the ESD or the
detection of free air by plain radiography or computed
tomography after the procedure.
Statistical Analysis
The Fisher’s exact test was used to compare categorical
variables between the cirrhotic and non-cirrhotic groups.
To compare continuous variables of the cirrhotic and non-
cirrhotic groups, the Mann–Whitney U test was used for
procedure time, while the independent Student’s t test was
used for continuous variables other than procedure time.
Statistical analyses were performed using SPSS software
(version 17.0; SPSS, Inc., Chicago, IL). A two-tailed
p value of\0.05 was considered statistically significant.
Results
The detailed results of carrying out ESD on the cirrhotic
patients are summarized in Table 1. SEN 1 had a dispro-
portionately long procedure time because this was the
second esophageal ESD case of the endoscopist. The
comparisons of patient and tumor characteristics between
the two groups are presented in Table 2. There were no
significant differences between the groups with regard to
age and gender. In cirrhotic group, the patients’ mean
serum level of albumin (3.9 vs. 4.3 g/dL, p = 0.002) and
mean platelet count (165.7 vs. 221.1 9 103/mm3,
p = 0.027) were significantly lower, while the mean
international normalized ratio value (1.23 vs. 1, p = 0.014)
was significantly higher than the same values for the non-
cirrhotic group. There were three, two, and six SENs
located at the upper, middle, and lower third of the
esophagus, respectively, in the cirrhotic group. The mean
tumor length was similar for the groups (4.0 vs. 3.7 cm,
p = 0.56).
None of the patients had ascites or hepatic
encephalopathy postoperatively. Table 3 lists the short-
term outcomes of the ESD treatment for both groups. The
medium procedure time was not statistically different
between the groups (15.1 vs. 11.5 min/cm2, p = 0.3). The
en bloc resection rate was also similar (9/11 or 81.8 % vs.
35/39 or 89.7 %, p = 0.6). There were two patients in the
cirrhotic group who did not undergo en bloc resection,

















1 1 A (5) 1.2 201 F-1 1.7 213.7 Yes pT1a-MM,
R0
Bleedingb
2 2 A (5) 1.1 99 F-1 4.0 21.8 Yes pT1b-SM2,
R0
Nil
3 2 A (6) 1.2 74 F-1 3.0 27.7 No pT1a-EP, Rx Nil
4 3 A (5) 1 386 No 2.6 20.2 Yes pT1b-SM2,
R0
Nil
5 2 A (6) 1.2 179 F-1 5.0 20.7 Yes pT1a-EP, R0 Nil
6 4 B (7) 1.5 58 F-2 5.0 7.2 Yes pT1b-SM2,
R1 (VM?)
Nil
7 5 B (9) 1.8 111 F-1 6.0 12.3 No cT1a, R2 Bleedingb
8 6 A (5) 1.2 134 No 2.9 15.1 Yes pT1b-SM2,
R0
nil
9 6 3.4 9.8 Yes pT1b-SM2,
R0
10 7 A (5) 1 245 No 4.9 11.4 Yes pT1b-SM2,
R1(VM?)
Nil
11 8 A (5) 1.1 141 No 5.8 10.5 Yes pT1a-MM,
R0
Nil
INR international normalized ratio, EVs esophageal varices, F-1 Form-1, F-2 Form-2, EP carcinoma in situ, MM tumor invading muscularis
mucosa, SM2 tumor invading the submucosa to a depth of more than 200 lm from the muscularis mucosa, R0 resection margins are free of
tumor, R1(VM?) positive vertical margins, R2 tumor cannot be completely removed endoscopically, Rx evaluation of free margins of the
specimens were impossible due to piecemeal resection
a SENs are numbered based on the ESD procedures’ chronological order
b Both suffered from intraprocedural bleeding and needed a blood transfusion
Dig Dis Sci (2016) 61:3565–3571 3567
123
these were SEN 3, which resulted in a piecemeal resection
due to the inexperience of the endoscopist and SEN 7
where there was a failure to remove due to the presence of
submucosal fibrosis caused by previous repeated EVLs.
The R0 resection rate was 7/9 versus 33/35 (77.8 vs.
94.3 %, p = 0.16). The two SENs (SEN 6 and 10) who did
not have a R0 resection in the cirrhotic group were positive
for vertical but not horizontal margins, because of deep
submucosal invasion by the tumors.
Two patients with coexisting EVs in the cirrhotic group
(SEN 1 and 7) required a blood transfusion (packed RBC
500 cc) during the ESD procedure (18.2 vs. 0 %,
p = 0.045). Both patients received blood transfusions
based on preexisting anemia (hemoglobin was 9–10 g/dL),
a full suction bottle (1000 cc/bottle), and the prolonged
procedure times (327 and 332 min, respectively). Frequent
bleeding occurred during both the mucosal incision and the
submucosal dissection. Transient spurting that lasted for
minutes even occurred during the circumferential submu-
cosal dissection for SEN 7. The inexperience of the
endoscopist and the fact that ESDs could be difficult due to
submucosal fibrosis were the main cause of the uncon-
trollable bleeding for SEN1 and SEN7, respectively.
However, none of the patients in either group had post-
procedural bleeding or esophageal perforation.
The postoperative pathological results and clinical out-
comes are listed in Table 1 and Table 3. The depth of
tumor invasion was subclassified according to the Japanese
Classification of Esophageal Cancer [4]. In the cirrhotic
group, two SENs were pT1a-EP (carcinoma in situ), two
SENs were pT1a-MM (tumor invading the muscularis
mucosa), and another six SENs were pT1b-SM2 (tumor
invading the submucosa to a depth of more than 200 lm
from the muscularis mucosa). There were six (54.5 %) and
ten (25.6 %) SENs with submucosal invasion in cirrhotic
and non-cirrhotic groups, respectively (p = 0.064). In cir-
rhotic group, two patients had a positive vertical resection
margin (SEN 6 and 10) and one patient (SEN 9) had
microvascular invasion. Among these three patients, one
(SEN 10) received surgical treatment and the other two
underwent concurrent chemoradiotherapy (CCRT). During
a mean follow-up period of 22.6 months (range,
6–30 months), two patients expired. One (SEN 7) died of
his synchronous tonsilar cancer at 6 months after the ESD
and the other one (SEN 2, 3, and 5) died of pneumonia at
bFig. 1 Relationship between esophageal neoplasm and varices (SEN
6). a White light endoscopy showing varices (green arrows) beneath
and near to the neoplasm (black arrows). b Endoscopic ultrasound
showing a varix (green arrows) beneath the neoplasm in the
submucosal layer. c After Lugol’s iodine staining, the varix cannot
be visualized
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22 months after the ESD. None of the patients in cirrhotic
group had tumor recurrence during the follow-up period.
Discussion
From the clinical perception, cirrhotic patients would seem
to be poor candidates for invasive procedures such as ESD
because of concerns about increased procedure-related
complications [11, 15]. However, several studies have
reported the feasibility of gastric ESD for patients with
liver cirrhosis, reporting post-procedural bleeding rates of
4.3–16.7 % and perforation rates of 0–1.5 % [16–20]. In
the present study of esophageal ESD for patients with liver
cirrhosis, no patient had post-procedural bleeding or per-
foration. It has been reported that platelet function or pri-
mary hemostasis are not necessarily defective in cirrhotic
patients [11, 21]. For elective invasive procedures, only
severe thrombocytopenia (\50 9 103/mm3) is used as a
cut-off value in terms of contraindications [21]. Our results
confirmed that esophageal ESD can be safely performed on
cirrhotic patients without severe thrombocytopenia [12].
Regarding esophageal ESD, our previous study revealed
that there is a significant learning curve [14]. Therefore, we
believed that the two SENs without en bloc resection can
have this fact attributed to the inexperience of the endo-
scopist during the early leaning period. This is supported
by the fact that the procedure time was significantly
Table 2 Patient and tumor
characteristics between cirrhotic
and non-cirrhotic groups
Liver cirrhosis (n = 11) Non-cirrhotic (n = 39) p value
Mean age, years (range) 57.6 (46–65) 53.7 (41–74) 0.14
Gender, male 8/8 31/32 1
Laboratory tests, mean level of
Albumin, g/dL (range) 3.9 (2.5–4.5) 4.3 (3.4–5.0) 0.002
Total bilirubin, mg/dL (range) 1.0 (0.2–2.7) 0.5 (0.2–1.4) 0.066
INR (range) 1.2 (1–1.8) 1.0 (0.9–1.1) 0.014
Platelet count, 9 103/mm3 (range) 165.7 (58–386) 221.1 (135–424) 0.027
Tumor location 0.58
Upper esophagus 3 (27.3 %) 7 (18.0 %)
Middle esophagus 2 (18.2 %) 13 (33.3 %)
Lower esophagus 6 (54.5 %) 19 (48.7 %)
Mean tumor length, cm (range) 4 (1.7–6) 3.7 (1.2–9.2) 0.56
INR—international normalized ratio
Table 3 Short-term outcomes
of ESD for both groups
Liver cirrhosis (n = 11) Non-cirrhotic (n = 39) p value
Median procedure time, min/cm2 (range) 15.1 (7.2–213.7) 11.5 (4.0–283.3) 0.30
En block resection (rate) 9 (81.8 %) 35 (89.7 %) 0.60
R0 resection (rate) 7/9 (77.8 %) 33/35 (94.3 %) 0.16
Complications
Perforation 0 0 1
Major bleeding 2 (18.2 %) 0 0.045
Pathological outcomes
Submucosal invasion 6 (54.5 %) 10 (25.6 %) 0.064
Lymphovascular invasion 1 (9.1 %) 2 (5.1 %) 0.42
CCRT after ESD 2/8 0 –
Esophagectomy after ESD 1/8 4/32 –
Mean follow-up period, months (range) 22.6 (6–30) 20.6 (1–42) 0.65
Recurrence 0 1 –
Deatha 2/8 2/32 –
CCRT concurrent chemoradiotherapy, ESD endoscopic submucosal dissection
a Three patients died of their synchronous head and neck cancers and one patient in cirrhotic group died of
pneumonia
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shortened for the later six SENs compared to the earlier
five SENs (median 10.9 vs. 24.7 min/cm2, p = 0.006).
However, the failure to carry out an en bloc resection with
SEN 7 was also due to the presence of esophageal fibrosis
caused by previously repeated EVL.
If we consider the en bloc resected specimens, a positive
vertical but not horizontal margin may be regarded as
tumor factor because of the possibility of deep submucosal
invasion, rather than this being attributable to a technique
failure of the ESD. In cirrhotic group, two SENs had
positive vertical margins but none had a positive horizontal
margin. Although there was a high rate (54.5 %) of SENs
with submucosal invasion in the cirrhotic group, none of
the patients had tumor recurrence during follow-up,
including the two patients receiving additional CCRT.
Given the fact that esophagectomy in cirrhotic patients is
associated with significant morbidity rates of 83–87 % and
mortality rates of 17–30 % [22], ESD combined CCRT
may be an alternative treatment for cirrhotic patients with
submucosal diseases.
Intraprocedural bleeding with or without the need of
blood transfusion did occur more significantly and fre-
quently when the patients had liver cirrhosis, especially
among those with visible EVs. This could be due to two
reasons. Firstly, despite the fact that we performed the EVL
just before the ESD, the varices were still present during
the ESD, although their sizes might have been decreased.
Eradication of varices usually requires two to four EVL
sessions [23]. Therefore, performing several sessions of
EVL before ESD, rather than just one session before ESD,
may be helpful in minimizing the EVs. Secondly, we used
an IT2 knife (Olympus) at specific cutting modes (40 W
ENDO-CUT mode with effect 2 using ERBE VIO 200 S or
40 W PULSE-CUT slow mode using Olympus ESG-400)
for most of the procedure including both mucosal incision
and submucosal dissection. Most of the larger varices could
be visualized and pretreated with the 80-W soft coagulation
mode using a Coagrasper (Olympus) or using a hot biopsy
forceps (Olympus). However, un-visualized or un-noticed
smaller vessels were still severed and this resulted in fre-
quent episodes of brisk bleeding compared to the non-cir-
rhosis patients. In cirrhotic patients without EVs visualized
on the preESD endoscopies, smaller varices could still be
found during mucosal incision and submucosal dissection
(Fig. 2). These frequent episodes of brisk bleeding resulted
in a need for frequent hemostatic procedures and increased
the difficulty carrying out the ESD; portal hypertension
was the presumptive cause [11, 24]. In these circumstances,
a combination of portal hypotensive agents and EVL may
be an effective method of reducing the severity and fre-
quency of bleeding during ESD. In the later cases, we used
the 40 W forced coagulation mode for the submucosal
dissection and this also resulted in less severe and frequent
bleeding. Further studies are needed to determine the best
solution to minimizing intraprocedural bleeding when cir-
rhotic patients are undergoing esophageal ESD.
The major limitation of the present study is the small case
number and the fact that their operations were performed in
a single center. However, because of concerns about
increased complications, cirrhotic patients with SENs
underwent ESD uncommonly and there has previously been
only one case series published in the literature [12]. There-
fore, we believe that prospective multicenter studies are
required to enroll a larger number of patients. The second
limitation is that we did not have patients with CP-C cir-
rhosis or patients with F-3 EVs, and therefore we do not
know whether it is feasible for patients with a poor liver
function reserve or large EVs to undergo esophageal ESD.
Fig. 2 (SEN 8) In cirrhotic patients without esophageal varices
visualized on the preESD endoscopies, smaller varices could still be
found during mucosal incision (a) and submucosal dissection (b)
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In conclusion, the results of this study indicated that
esophageal ESD can be safely and effectively performed in
patients with liver cirrhosis by an experienced ESD endo-
scopist, at least when the patients are without severe liver
dysfunction or large EVs.
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